Non-Segmental Vitiligo (NSV), Vitiligo research hub

J5D-MC-FPAD: A Phase 2a, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo

This study is testing a new medicine, LY4005130, for adults with vitiligo, a skin condition causing white patches. It aims to see if the medicine can help reduce face vitiligo and if it’s safe to use. Half the participants will get the medicine, and half a dummy treatment.